<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MiniPDX &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/minipdx/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 13 Oct 2026 16:44:58 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>MiniPDX &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Virtual Tumors Point to New Drug Combinations for Hard-to-Treat Lung Cancer Mutations</title>
		<link>https://bioengineer.org/virtual-tumors-point-to-new-drug-combinations-for-hard-to-treat-lung-cancer-mutations/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 13 Oct 2026 16:44:58 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[BRAF mutations]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[drug resistance]]></category>
		<category><![CDATA[ERK inhibitors]]></category>
		<category><![CDATA[MAPK pathway]]></category>
		<category><![CDATA[MEK inhibitors]]></category>
		<category><![CDATA[MiniPDX]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[quantitative systems pharmacology]]></category>
		<category><![CDATA[RAF inhibitors]]></category>
		<category><![CDATA[virtual clinical trials]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=417626</guid>

					<description><![CDATA[A new quantitative systems pharmacology model spanning all three classes of BRAF-mutant lung cancer predicts that MEK-ERK inhibitor combinations can treat the half of patients whose non-V600 mutations currently lack targeted therapy options, a prediction validated in mice carrying real patient tumors.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">417626</post-id>	</item>
	</channel>
</rss>
